Development of 111In-DTPA-human polyclonal antibody complex for long-term inflammation/infection detection

• Autorzy: Jalilian A. , Rowshanfarzad P. , Shafaii K. , Kamali-Dehghan M. , Moafian J. , Akhlaghi M. , Babaii M. , Rajabifar S. , Mirzaii M.
• Języki publikacji: EN

Abstrakty

EN

Human polyclonal antibody (HIgG) was successively labeled with 111In-indium chloride after residulation with freshly prepared cyclic DTPA-dianhydride. The best results of the conjugation were obtained by the addition of solid DTPA-dianhydride (0.1 0.3 mg) to 100 mi l of the HIgG solution (0.2 0.4 mg/ml) at pH = 6 in phosphate buffer media at 25°C with continuous stirring for 30 min. Radio-thin-layer chromatography showed an overall radiochemical yield of 96 99% at optimized conditions (specific activity = 300 500 MBq/mg, radiochemical purity >98%). The final isotonic 111In-DTPA-HIgG complex was checked by radio-TLC to ensure the formation of only one species followed by filtration through a 0.22 mi filter. Preliminary long-term in vivo studies in turpentine-oil induced inflammation in rat model was performed to determine late complex distribution of the radioimmunoconjugate. The target/skin and target/ blood ratios were 27 and 51 after 24 h, and 23 and 51 after 110 h, showing a high selectivity of the radiopharmaceutical for inflammatory lesions.

Słowa kluczowe

EN

radiopharmaceuticals; indium-111; human polyclonal antibody; inflammation; turpentine oil

• Wydawca: Institute of Nuclear Chemistry and Technology
• Czasopismo: Nukleonika
• Rocznik: 2005
• Tom: Vol. 50, nr 3
• Strony: 91--96
• Opis fizyczny: Bibliogr. 20 poz., rys.

Twórcy

autor

Jalilian A.

• Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran, P. O. Box 31485-498, Tel./Fax: [phone]

autor

Rowshanfarzad P.

• Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran, P. O. Box 31485-498, Tel./Fax: [phone]

autor

Shafaii K.

• Nuclear Agriculture Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran

autor

Kamali-Dehghan M.

• Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran, P. O. Box 31485-498, Tel./Fax: [phone]

autor

Moafian J.

• Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran, P. O. Box 31485-498, Tel./Fax: [phone]

autor

Akhlaghi M.

• Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran, P. O. Box 31485-498, Tel./Fax: [phone]

autor

Babaii M.

• Nuclear Research Center, Atomic Energy Organization of Iran (AEOI), North-Kargar Str., Tehran, Iran

autor

Rajabifar S.

• Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran, P. O. Box 31485-498, Tel./Fax: [phone]

autor

Mirzaii M.

• Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran, P. O. Box 31485-498, Tel./Fax: [phone]

Bibliografia

• 1. Buscombe JR, Oyen WJ, Grant A et al.(1993) Indium-111-labeled polyclonal human immunoglobulin: identifying focal infection in patients positive for human immunodeficiency virus. J Nucl Med 34;10:1621−1625.
• 2. de Kleijn EM, Oyen WJ, Claessens RA, Corstens FH, van der Meer JW (1995) Utility of scintigraphic methods in patients with fever of unknown origin. Arch Intern Med155;18:1989−1994.
• 3. Eckelman WC, Karesh SM, Reba RC (1975) New compounds: fatty acid and long chain hydrocarbon derivatives containing a strong chelating agent. J Pharm Sci 64;4:704−706.
• 4. Fischman AJ, Fucello AJ, Pellegrino-Gensey JL et al. (1992) Effect of carbohydrate modification on the localization of human polyclonal IgG at focal sites of bacterial infection. J Nucl Med 33;7:1378−1382.
• 5. Fischman AJ, Rubin RH, White JA et al. (1990) Localization of Fc and Fab fragments of nonspecific polyclonal IgG at focal sites of inflammation. J Nucl Med 31;7:1199−1205.
• 6. Hnatowich DJ, Layne WW, Child RL (1983) Radioactive labeling of antibody: a simple and efficient method. Science 220:613−619.
• 7. http://www.docguide.com/dg.nsf/PrintPrint/150749630B95133B85256372004AC561.
• 8. http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01138.html.
• 9. http://www.fda.gov/bbs/topics/ANSWERS/ANS00463.html.
• 10. Khawli LA, Allaudin MM, Peisheng H, Epstein AL (2003) Tumor targeting properties of 111In-labeled genetically engineered Fab’ and constructs of chimeric tumor necrosis treatment antibody. Cancer Biother Radiother 18:931−940.
• 11. Kladnik S, Budihna NV, Batagelj I, Gubina M (1997) Separation and technetium labeling of autologous poly-clonal immunoglobulin G. Nucl Med Biol 24;6:535−538.
• 12. Lai J, Quadri SM, Borchardt PE et al. (1999) Pharmaco-kinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin’s disease. Clin Cancer Res 5:3315s−3323s.
• 13. Mairal L, de Lima PA, Martin-Comin J et al. (1995) Simultaneous administration of 111In-human immuno-globulin and 99mTc-HMPAO labelled leucocytes in inflammatory bowel disease. Eur J Nucl Med 22;7:664−700.
• 14. Marczenko Z (1976) Spectrophotometric determination of elements. John Wiley & Sons Inc, New York.
• 15. Mirzaii M, Afarideh H, Haji-Saied SM, Ardaneh K (1998) Production of 111In by irradiation of natural cadmium with deuterons and protons in NRCAM cyclotron. In: Proc on 15th Int Conf on Cyclotrons and their Applications,14−19 June 1998, Caen, France, pp 65−67.
• 16. Nijhof MW, Oyen WJ, van Kampen A, Claessens RA, van der Meer JW, Corstens FH (1997) Evaluation of infections of the locomotor system with indium-111-labeled human IgG scintigraphy. J Nucl Med 38:1300−1305.
• 17. Oyen WJ, Claessens RA, Raemaekers JM, de Pauw BE, van der Meer JW, Corstens FH (1992) Diagnosing infection in febrile granulocytopenic patients with indium-111-labeled human immunoglobulin G. J Clin Oncol 10;1:61−68.
• 18. Pain SJ, Barber RW, Ballinger JR et al. (2004) Tissue-to-blood transport of radiolabelled immunoglobulin injected into the web spaces of the hands of normal subjects and patients with breast cancer-related lymphedema. J Vasc Res 41;2:183−192.
• 19. Pain SJ, Nicholas RS, Barber RW et al. (2002) Quantification of lymphatic function for investigation of lymphedema: depot clearance and rate of appearance of soluble macromolecules in blood. J Nucl Med 43:318−324.
• 20. Rubin RH, Fischman AJ, Callahan RJ et al. (1989) 111 In-labeled nonspecific immunoglobulin scanning in the detection of focal infection. New Engl J Med 321;14:935−940.